RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kyowa Kirin Co - Stock

Kyowa Kirin Co ROE 2024

Kyowa Kirin Co ROE

0.1

Ticker

4151.T

ISIN

JP3256000005

WKN

858523

In 2024, Kyowa Kirin Co's return on equity (ROE) was 0.1, a 38.21% increase from the 0.07 ROE in the previous year.

Kyowa Kirin Co Aktienanalyse

What does Kyowa Kirin Co do?

Kyowa Kirin Co Ltd is a Japanese pharmaceutical company that was founded over 70 years ago. The company is headquartered in Tokyo and has been listed on the stock exchange since 1974. It has over 6,000 employees worldwide and conducts research and development in the fields of bioscience and biotechnology. The history of Kyowa Kirin Co Ltd began in 1949 when the company was established as Kyowa Hakko Seiyaku Co Ltd. Initially, the company primarily focused on the production of pharmaceutical products and chemicals. In the 1990s, the company expanded globally and announced a focus on researching novel drugs. Today, Kyowa Kirin Co Ltd is a leading company in bioscience and biotechnology, offering a wide range of products and services. The company is divided into several business segments, including pharmaceuticals, biopharmaceuticals, and diagnostics. Kyowa Kirin Co Ltd has a comprehensive product range, from the asthma medication Nucala to the hearing loss medication Nouriast®. Nucala is an innovative medication for the treatment of severe asthma and was approved by the FDA in 2015. The medication has proven to be highly effective in clinical studies and has the potential to improve the lives of millions of people. Another important product from Kyowa Kirin Co Ltd is the cancer medication Mogamulizumab. The medication is used for the treatment of T-cell lymphomas, a rare form of lymph node cancer. Mogamulizumab was approved in Japan in 2012 and has since proven to be an effective medication in treating T-cell lymphomas. The company also conducts research and development in the field of regenerative medicine. An example of this is the medication Regsorin, which is used for the treatment of peripheral vascular diseases. Regsorin is a biologic made from the body's own fibronectin protein and is able to strengthen and repair blood vessels and capillaries. Another important business area for Kyowa Kirin Co Ltd is diagnostics. The company produces and distributes diagnostic tests for a range of diseases, including allergies, infectious diseases, and cancer. The diagnostics division of Kyowa Kirin Co Ltd works closely with the company's other business segments to develop and market innovative diagnostic tests. Overall, Kyowa Kirin Co Ltd is an outstanding example of a pharmaceutical company specializing in the research and development of novel drugs and therapies for serious diseases. The company has an impressive history of innovation over the decades and has established itself as a leading provider in biosciences and biotechnology. With its wide product range and innovative research efforts, Kyowa Kirin Co Ltd is a key player in the global market for medical therapies and diagnostics. Kyowa Kirin Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Kyowa Kirin Co's Return on Equity (ROE)

Kyowa Kirin Co's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Kyowa Kirin Co's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Kyowa Kirin Co's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Kyowa Kirin Co’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Kyowa Kirin Co Stock

What is the ROE (Return on Equity) of Kyowa Kirin Co this year?

The ROE of Kyowa Kirin Co this year is 0.1 undefined.

How has the Return on Equity (ROE) of Kyowa Kirin Co developed compared to the previous year?

The ROE of Kyowa Kirin Co has increased by 38.21% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Kyowa Kirin Co?

A high ROE indicates that Kyowa Kirin Co generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Kyowa Kirin Co?

A low ROE can indicate that Kyowa Kirin Co is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Kyowa Kirin Co affect the company?

A change in ROE (Return on Equity) of Kyowa Kirin Co can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Kyowa Kirin Co?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Kyowa Kirin Co?

Some factors that can influence Kyowa Kirin Co's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Kyowa Kirin Co pay?

Over the past 12 months, Kyowa Kirin Co paid a dividend of 56 JPY . This corresponds to a dividend yield of about 2.04 %. For the coming 12 months, Kyowa Kirin Co is expected to pay a dividend of 57.97 JPY.

What is the dividend yield of Kyowa Kirin Co?

The current dividend yield of Kyowa Kirin Co is 2.04 %.

When does Kyowa Kirin Co pay dividends?

Kyowa Kirin Co pays a quarterly dividend. This is distributed in the months of July, January, July, January.

How secure is the dividend of Kyowa Kirin Co?

Kyowa Kirin Co paid dividends every year for the past 23 years.

What is the dividend of Kyowa Kirin Co?

For the upcoming 12 months, dividends amounting to 57.97 JPY are expected. This corresponds to a dividend yield of 2.11 %.

In which sector is Kyowa Kirin Co located?

Kyowa Kirin Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kyowa Kirin Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kyowa Kirin Co from 3/1/2025 amounting to 29 JPY, you needed to have the stock in your portfolio before the ex-date on 12/27/2024.

When did Kyowa Kirin Co pay the last dividend?

The last dividend was paid out on 3/1/2025.

What was the dividend of Kyowa Kirin Co in the year 2023?

In the year 2023, Kyowa Kirin Co distributed 51 JPY as dividends.

In which currency does Kyowa Kirin Co pay out the dividend?

The dividends of Kyowa Kirin Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Kyowa Kirin Co

Our stock analysis for Kyowa Kirin Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kyowa Kirin Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.